BrUOG 263: PSMA ADC for Recurrent Glioblastoma Multiforme (GBM): A Phase II Brown University Oncology Research Group Study

Trial Profile

BrUOG 263: PSMA ADC for Recurrent Glioblastoma Multiforme (GBM): A Phase II Brown University Oncology Research Group Study

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs PSMA ADC (Primary)
  • Indications Glioblastoma; Gliosarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 19 Jun 2015 Status changed from active, no longer recruiting to completed.
    • 24 Nov 2014 Planned End Date changed from 1 Oct 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top